June Kaplow
About
June Kaplow is a scholar working on Physiology, Molecular Biology and Pharmacology.
According to data from OpenAlex, June Kaplow has authored 46 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Physiology, 18 papers in Molecular Biology and 12 papers in Pharmacology. Recurrent topics in June Kaplow's work include Alzheimer's disease research and treatments (25 papers), Cholinesterase and Neurodegenerative Diseases (11 papers) and Computational Drug Discovery Methods (10 papers). June Kaplow is often cited by papers focused on Alzheimer's disease research and treatments (25 papers), Cholinesterase and Neurodegenerative Diseases (11 papers) and Computational Drug Discovery Methods (10 papers). June Kaplow collaborates with scholars based in United States, United Kingdom and Japan. June Kaplow's co-authors include Michael Jaye, Joseph Schlessinger, Craig A. Dionne, Gregg Crumley, Wilson H. Burgess, F. Bellot, M Ruta, Robert Lai, Chad J. Swanson and Lars Lannfelt and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The EMBO Journal.
In The Last Decade
June Kaplow
45 papers receiving 2.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| June Kaplow United States | 18 | 1.3k | 890 | 471 | 395 | 319 | 46 | 2.4k | ||
| Olav M. Andersen Denmark | 26 | 1.4k 1.1× | 1.4k 1.6× | 812 1.7× | 190 0.5× | 100 0.3× | 63 | 2.9k | ||
| Grégory Raux France | 19 | 1.1k 0.8× | 1.1k 1.3× | 104 0.2× | 270 0.7× | 263 0.8× | 27 | 2.3k | ||
| Agueda Rostagno United States | 38 | 2.3k 1.7× | 2.8k 3.2× | 391 0.8× | 377 1.0× | 268 0.8× | 97 | 4.6k | ||
| Christine Sato Canada | 28 | 936 0.7× | 943 1.1× | 178 0.4× | 165 0.4× | 119 0.4× | 66 | 2.3k | ||
| Jennie Taylor United States | 22 | 1.2k 0.9× | 1.2k 1.4× | 117 0.2× | 211 0.5× | 201 0.6× | 91 | 3.1k | ||
| Midori OGAWARA Japan | 13 | 1.0k 0.8× | 1.2k 1.3× | 405 0.9× | 199 0.5× | 82 0.3× | 30 | 1.9k | ||
| Mary J. Savage United States | 31 | 1.3k 1.0× | 1.8k 2.0× | 188 0.4× | 454 1.1× | 306 1.0× | 67 | 4.7k | ||
| Jianhua Shi China | 24 | 1.3k 1.0× | 775 0.9× | 222 0.5× | 190 0.5× | 68 0.2× | 49 | 2.1k | ||
| Yuling Sun China | 20 | 1.2k 0.9× | 662 0.7× | 98 0.2× | 153 0.4× | 124 0.4× | 51 | 2.6k | ||
| Tomoko Kurata Japan | 27 | 1.2k 0.9× | 396 0.4× | 177 0.4× | 113 0.3× | 125 0.4× | 87 | 2.5k |
Countries citing papers authored by June Kaplow
Since
Specialization
Citations
This map shows the geographic impact of June Kaplow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by June Kaplow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites June Kaplow more than expected).
Fields of papers citing papers by June Kaplow
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by June Kaplow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by June Kaplow. The network helps show where June Kaplow may publish in the future.
Co-authorship network of co-authors of June Kaplow
This figure shows the co-authorship network connecting the top 25 collaborators of June Kaplow. A scholar is included among the top collaborators of June Kaplow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with June Kaplow. June Kaplow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cline, Erika N., Karen Sundell, Elizabeth A. Johnson, et al.. (2025). Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 12(4). 100082–100082.
2.
Bullich, Santiago, André Mueller, Susan De Santi, et al.. (2022). Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study. Alzheimer s Research & Therapy. 14(1). 105–105.
3.
Roberts, Charles T., et al.. (2021). Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program. The Journal of Prevention of Alzheimer s Disease. 8(2). 218–223.
4.
Irizarry, Michael C., Shobha Dhadda, Tanya Bogoslovsky, et al.. (2021). BASELINE CHARACTERISTICS FOR CLARITY-AD: A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 18-MONTH STUDY EVALUATING BAN2401 IN EARLY ALZHEIMER’S DISEASE (3021). Neurology. 96(15_supplement).
5.
Swanson, Chad J., Yong Zhang, Shobha Dhadda, et al.. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer s Research & Therapy. 13(1). 80–80.
6.
Irizarry, Michael C., Shobha Dhadda, Michio Kanekiyo, et al.. (2021). Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. Alzheimer s & Dementia. 17(S9).
7.
Swanson, Chad J., Yong Zhang, Shobha Dhadda, et al.. (2020). A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer’s disease. Alzheimer s & Dementia. 16(S9).
8.
Swanson, Chad J., Yong Zhang, Shobha Dhadda, et al.. (2020). Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease (1330). Neurology. 94(15_supplement).
9.
Molinuevo, José Luís, Akihiko Koyama, Shobha Dhadda, et al.. (2019). DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY. Alzheimer s & Dementia. 15(7S_Part_28).
10.
Logovinsky, Veronika, Andrew Satlin, Robert Lai, et al.. (2016). Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer s Research & Therapy. 8(1). 14–14.
11.
Savage, Mary J., Daniel Holder, Guoxin Wu, et al.. (2015). Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer’s Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer’s Disease Neuroimaging Initiative-1 Baseline Cohort. Journal of Alzheimer s Disease. 46(2). 431–440.
12.
Swanson, Chad J., June Kaplow, Diego Mastroeni, et al.. (2013). P4–286: Pharmacology of BAN2401: A monoclonal antibody selective for beta‐amyloid protofibrils. Alzheimer s & Dementia. 9(4S_Part_20).
13.
Navia, Bradford, Carlos Perdomo, June Kaplow, et al.. (2013). P4–282: A multimodal imaging study of mAb158, a murine monoclonal antibody with high selectivity for amyloid protofibrils, in Tg2576 mice. Alzheimer s & Dementia. 9(4S_Part_20).
14.
Savage, Mary J., Dan Holder, Guoxin Wu, et al.. (2013). P1–140: Soluble BACE activity and sAPPβ levels do not differentiate Alzheimer's disease and age‐matched control cerebrospinal fluid in the ADNI‐1 cohort. Alzheimer s & Dementia. 9(4S_Part_5).
15.
Rodríguez-Granillo, Gastón A., Serruys Pw, Dick Goedhart, et al.. (2005). First-in-man prospective evaluation of temporal changes in coronary plaque composition by in vivo intravascular ultrasound radiofrequency data analysis: an Integrated Biomarker and Imaging Study (IBIS) substudy.. PubMed. 1(3). 282–8.
16.
Hu, Yun‐Fu, et al.. (2005). From Traditional Biomarkers to Transcriptome Analysis in Drug Development. Current Molecular Medicine. 5(1). 29–38.
17.
Osei, Kwame, Trudy Gaillard, June Kaplow, Matthew Bullock, & Dara Schuster. (2004). Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism. 53(12). 1552–1557.
18.
Hamel, L T, Zaid Jayyosi, Ali Ardati, et al.. (2000). Induction of heat shock protein 70 by herbimycin A and cyclopentenone prostaglandins in smooth muscle cells. Cell Stress and Chaperones. 5(2). 121–121.
19.
Kaplow, June, et al.. (1997). Ligand‐binding specificity of human fibroblast growth factor receptor‐3 IIIc. FEBS Letters. 411(2-3). 389–392.
20.
Kaplow, June, et al.. (1990). Effect of heparin on the binding affinity of acidic FGF for the cloned human FGF receptors, flg and bek. Biochemical and Biophysical Research Communications. 172(1). 107–112.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Olav M. Andersen Breakdown of academic impact, for papers by Grégory Raux Breakdown of academic impact, for papers by Agueda Rostagno Breakdown of academic impact, for papers by Christine Sato Breakdown of academic impact, for papers by Jennie Taylor Breakdown of academic impact, for papers by Midori OGAWARA Breakdown of academic impact, for papers by Mary J. Savage Breakdown of academic impact, for papers by Jianhua Shi Breakdown of academic impact, for papers by Yuling Sun Breakdown of academic impact, for papers by Tomoko Kurata